Skip to content

HealthEquity HQY Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

UnitedHealth Group logo
UnitedHealth GroupUNH
Webster Financial Corporation logo
Webster Financial CorporationWBS
Voya Financial logo
Voya FinancialVOYA
CVS Health logo
CVS HealthCVS
MetLife logo
MetLifeMET

Other financials

Income statement

See full
Revenue$354.6M+7.2%
Gross profit$256.3M+14.3%
Operating income$103.0M+23.9%
Net income$69.4M+28.8%
EPS (diluted)$0.82+34.4%

Balance sheet

See full
Cash & equivalents$265.4M-7.8%
Total debt$984.7M-11.0%
Total equity$2.0B-3.6%
Total assets$3.3B-3.2%

Cash flow

See full
Operating cash flow$97.5M+50.6%
CapEx$362.0K+321%
Free cash flow$97.2M+50.3%

Valuation

See full
Market cap$7.12B-6.7%
Enterprise value$7.84B-7.2%
P/E30.9×-31.8×
P/S5.3×-0.8×

Profitability

See full
Gross margin70.7%+5.2pp
Operating margin25.6%+9.2pp
Net margin17.3%+7.5pp
FCF margin36.5%+9.3pp

Returns & leverage

See full
Return on equity11.1%+5.3pp
Debt / equity0.5×0.0×
Current ratio3.4×-0.6×

Where this comes from

Reported directly by HealthEquity in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: HealthEquity’s 10-Q, filed May 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about HealthEquity's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is HealthEquity's common stock, shares authorized (in shares)?
HealthEquity (HQY) reported common stock, shares authorized (in shares) of $900M in Q1 2026.
How has HealthEquity's common stock, shares authorized (in shares) changed year-over-year?
HealthEquity's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $900M to $900M.
What is the long-term trend for HealthEquity's common stock, shares authorized (in shares)?
Over 5 years (2021 to 2026), HealthEquity's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $900M to $900M.